GlassScriptPhysician profile
Masood Ghouse
NPI 1215120928
$7,936.99
in general payments reported to CMS, 2019-2025
55 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $537 · 2021: $638 · 2022: $1,237 · 2023: $1,983 · 2024: $1,878 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,758 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,757.61 |
| Education | $218.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $610.11 | 2020-2025 | Tagrisso, Lynparza, Enhertu |
| Pfizer INC. | $549.73 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $501.52 | 2019-2025 | Opdivo, Eliquis |
| Janssen Biotech, INC. | $478.19 | 2019-2025 | Darzalex, Rybrevant, Talvey |
| Novartis Pharmaceuticals Corporation | $451.27 | 2021-2024 | |
| Incyte Corporation | $422.75 | 2019-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $407.43 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $378.53 | 2020-2025 | Padcev, Xtandi |
| Glaxosmithkline, LLC. | $310.31 | 2020-2024 | Benlysta, Jemperli, Ojjaara |
| Celgene Corporation | $248.39 | 2022-2025 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $224.22 | 2021-2025 | Polivy, Lunsumio, Columvi |
| Seagen INC. | $216.58 | 2021-2023 | Tukysa, Padcev |
| Lilly USA, LLC | $214.29 | 2020-2024 | Jaypirca, Retevmo, Verzenio |
| Gilead Sciences, INC. | $203.26 | 2021-2025 | Trodelvy |
| Amgen INC. | $201.84 | 2019-2023 | Xgeva, Nplate, Vectibix |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Masood Ghouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.